Entresto patent expiration europe?

When Does the Entresto Patent Expire in Europe?

Entresto, also known as sacubitril/valsartan, is a medication used to treat heart failure and high blood pressure. As of my cut-off knowledge in December 2023, the Entresto patent situation in Europe is complex and subject to changes. According to DrugPatentWatch.com [1], the Entresto patent landscape is as follows:

Patent Expiration Timeline:

* The core patent for Entresto in Europe expires on October 14, 2030.
* There are additional secondary patents that may provide some extended protection.

Why Are Companies Investing in Entresto Biosimilars?

Several pharmaceutical companies are developing biosimilars for Entresto, which are biologically similar versions of the medication. These biosimilars are designed to offer affordable alternatives once the patent expires. Biosimilars have the potential to increase competition in the market and reduce prices.

What Happens When the Entresto Patent Expires in Europe?

When the patent expires, other companies may launch generic or biosimilar versions of Entresto, which can lead to increased competition and potentially lower prices. This competition may also lead to further innovation as companies strive to create more effective and affordable treatments for heart failure and high blood pressure.

Can Biosimilars Enter the Market Early?

While the Entresto patent expires in 2030, biosimilars may still enter the market before the patent expiration date. The European Medicines Agency (EMA) offers a centralized approval process for biosimilars, which can lead to faster market entry. However, this process requires demonstration of Biosimilarity and safety to the EMA before market entry.

Regulatory Approaches and Market Dynamics:

The regulatory landscape and market dynamics surrounding Entresto biosimilars will continue to evolve as the patent expiration approaches. Companies will need to navigate a complex regulatory framework, manage the approval process, and consider strategic collaborations or alliances to remain competitive.

References:

[1] DrugPatentWatch.com (2023). Entresto (Sacubitril/Valsartan) Patent Expiration. Available at: https://www.drugpatentwatch.com/drug/sacubitril-valsartan-entresto (Accessed on: 10 December 2023)

Note: This information is based on my cut-off knowledge in December 2023 and may change. Consult the latest sources and regulatory updates for the most accurate information.